| [1] | PALUNCIC J, KOVACEVIC Z, JANSSON P J, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling[J]. Biochim Biophys Acta, 2016, 1863(4): 770-784. doi: 10.1016/j.bbamcr.2016.01.025 |
| [2] | ZHANG S W, SUN K X, ZHENG R S, et al. Cancer incidence and mortality in China, 2015[J]. J Natl Cancer Cent, 2021, 1(1): 2-11. doi: 10.1016/j.jncc.2020.12.001 |
| [3] | 高天文, 郭伟楠. 中国黑素瘤研究进展与新治疗策略[J]. 中华皮肤科杂志, 2021, 54(1): 27-32. |
| [4] | OLBRYT M, PIGŁOWSKI W, RAJCZYKOWSKI M, et al. Genetic profiling of advanced melanoma: candidate mutations for predicting sensitivity and resistance to targeted therapy[J]. Targ Oncol, 2020, 15(1): 101-113. doi: 10.1007/s11523-020-00695-0 |
| [5] | SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1): 17-48. doi: 10.3322/caac.21763 |
| [6] | WEISS S A, WOLCHOK J D, SZNOL M. Immunotherapy of melanoma: facts and hopes[J]. Clin Cancer Res, 2019, 25(17): 5191-5201. doi: 10.1158/1078-0432.CCR-18-1550 |
| [7] | GUO C Q, MANJILI M H, SUBJECK J R, et al. Therapeutic cancer vaccines: past, present, and future[J]. Adv Cancer Res, 2013, 119: 421-475. |
| [8] | SCHWARTZENTRUBER D J, LAWSON D H, RICHARDS J M, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma[J]. N Engl J Med, 2011, 364(22): 2119-2127. doi: 10.1056/NEJMoa1012863 |
| [9] | BUTTERFIELD L H, VUJANOVIC L, SANTOS P M, et al. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma[J]. J Immunother Cancer, 2019, 7(1): 113. doi: 10.1186/s40425-019-0552-x |
| [10] | DING Z Y, LI Q, ZHANG R, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 26. doi: 10.1038/s41392-020-00448-5 |
| [11] | MOSAHEB M M, BROWN M C, DOBRIKOVA E Y, et al. Harnessing virus tropism for dendritic cells for vaccine design[J]. Curr Opin Virol, 2020, 44: 73-80. doi: 10.1016/j.coviro.2020.07.012 |
| [12] | MIRANDA L, Broz, . Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity[J]. Cancer Cell, 2014, 26(5): 638-652. doi: 10.1016/j.ccell.2014.09.007 |
| [13] | 肖鹏, 曹雪涛, 王青青. 恶性肿瘤免疫治疗的现状及展望[J]. 实用肿瘤杂志, 2016, 31(1): 5-9. doi: 10.13267/j.cnki.syzlzz.2016.01.003 |
| [14] | Hélène, Salmon, . Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition[J]. Immunity, 2016, 44(4): 924-938. doi: 10.1016/j.immuni.2016.03.012 |
| [15] | KWAK M, LEICK K M, MELSSEN M M, et al. Vaccine strategy in melanoma[J]. Surg Oncol Clin N Am, 2019, 28(3): 337-351. doi: 10.1016/j.soc.2019.02.003 |
| [16] | Roberts E, Broz M, Binnewies M, et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma[J]. Cancer Cell, 2016: 324-336. doi: 10.1016/j.ccell.2016.06.003 |
| [17] | GARDNER A, DE MINGO PULIDO Á, RUFFELL B. Dendritic cells and their role in immunotherapy[J]. Front Immunol, 2020, 11: 924. doi: 10.3389/fimmu.2020.00924 |
| [18] | WCULEK S K, CUETO F J, MUJAL A M, et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2020, 20(1): 7-24. doi: 10.1038/s41577-019-0210-z |
| [19] | PATIDAR A, SELVARAJ S, SARODE A, et al. DAMP-TLR-cytokine axis dictates the fate of tumor[J]. Cytokines, 2018, 104: 114-123. doi: 10.1016/j.cyto.2017.10.004 |
| [20] | JONGBLOED S L, KASSIANOS A J, MCDONALD K J, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens[J]. J Exp Med, 2010, 207(6): 1247-1260. doi: 10.1084/jem.20092140 |
| [21] | GUILLIAMS M, GINHOUX F, JAKUBZICK C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny[J]. Nat Rev Immunol, 2014, 14(8): 571-578. doi: 10.1038/nri3712 |
| [22] | COLLIN M, BIGLEY V. Human dendritic cell subsets: an update[J]. Immunology, 2018, 154(1): 3-20. doi: 10.1111/imm.12888 |
| [23] | VanDeLaar, L, Coffer, et al. Regulation of dendritic cell development by GM-CSF: Molecular control and implications for immune homeostasis and therapy[J]. Blood the Journal of the American Society of Hematology, 2012. doi: 10.1182/blood-2011-11-370130 |
| [24] | SCHULER G. Dendritic cells in cancer immunotherapy[J]. Eur J Immunol, 2010, 40(8): 2123-2130. doi: 10.1002/eji.201040630 |
| [25] | RODRÍGUEZ PÉREZ Á, CAMPILLO-DAVO D, VAN TENDELOO V F I, et al. Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment[J]. Clin Transl Oncol, 2020, 22(11): 1923-1937. doi: 10.1007/s12094-020-02344-4 |
| [26] | SAADELDIN M K, ABDEL-AZIZ A K, ABDELLATIF A. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis[J]. Med Hypotheses, 2021, 146: 110365. doi: 10.1016/j.mehy.2020.110365 |
| [27] | PALUCKA A K, UENO H, CONNOLLY J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity[J]. J Immunother, 2006, 29(5): 545-557. doi: 10.1097/01.cji.0000211309.90621.8b |
| [28] | SABADO R L, BHARDWAJ N. Dendritic cell immunotherapy[J]. Ann NY Acad Sci, 2013, 1284(1): 31-45. doi: 10.1111/nyas.12125 |
| [29] | MIURA R, SAWADA S I, MUKAI S A, et al. Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody[J]. RSC Adv, 2020, 10(14): 8074-8079. doi: 10.1039/C9RA10066K |
| [30] | YI D H, APPEL S. Current status and future perspectives of dendritic cell-based cancer immunotherapy[J]. Scand J Immunol, 2013, 78(2): 167-171. doi: 10.1111/sji.12060 |
| [31] | LEE M, PARK C S, LEE Y R, et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells[J]. Arch Pharm Res, 2014, 37(9): 1234-1240. doi: 10.1007/s12272-014-0379-4 |
| [32] | Beek J J P V, Georgina Flórez-Grau, Gorris M A J, et al. Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination[J]. Cell Reports, 2020, 304): 1027-1038. e4. doi: 10.1016/j.celrep.2019.12.096 |
| [33] | DILLMAN R O, CORNFORTH A N, DEPRIEST C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma[J]. J Immunother, 2012, 35(8): 641-649. doi: 10.1097/CJI.0b013e31826f79c8 |
| [34] | SQUADRITO M L, CIANCIARUSO C, HANSEN S K, et al. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens[J]. Nat Methods, 2018, 15(3): 183-186. doi: 10.1038/nmeth.4579 |
| [35] | CARRENO B M, MAGRINI V, BECKER-HAPAK M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells[J]. Science, 2015, 348(6236): 803-808. doi: 10.1126/science.aaa3828 |
| [36] | ZUPANČIČ E, CURATO C, KIM J S, et al. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer[J]. Nanomedicine, 2018, 14(3): 835-847. doi: 10.1016/j.nano.2017.12.011 |
| [37] | YAZDANI M, JAAFARI M R, VERDI J, et al. Ex vivo- generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems[J]. Immunotherapy, 2020, 12(5): 333-349. doi: 10.2217/imt-2019-0173 |
| [38] | PAYANDEH Z, YARAHMADI M, NARIMAN-SALEH-FAM Z, et al. Immune therapy of melanoma: overview of therapeutic vaccines[J]. J Cell Physiol, 2019, 234(9): 14612-14621. doi: 10.1002/jcp.28181 |
| [39] | Celluzzi C M, Falo L D. Epidermal Dendritic Cells Induce Potent Antigen-Specific CTL-Mediated Immunity[J]. Journal of Investigative Dermatology, 1997, 108(5): 716-720. doi: 10.1111/1523-1747.ep12292095 |
| [40] | S, Wilgenhof. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients[J]. Annals of Oncology, 2013. doi: 10.1093/annonc/mdt245 |
| [41] | WILGENHOF S, CORTHALS J, HEIRMAN C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma[J]. J Clin Oncol, 2016, 34(12): 1330-1338. doi: 10.1200/JCO.2015.63.4121 |
| [42] | WILGENHOF S, CORTHALS J, VAN NUFFEL A M T, et al. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases[J]. Cancer Immunol Immunother, 2015, 64(3): 381-388. doi: 10.1007/s00262-014-1642-8 |
| [43] | FANG P, LI X Y, DAI J, et al. Immune cell subset differentiation and tissue inflammation[J]. J Hematol Oncol, 2018, 11(1): 97. doi: 10.1186/s13045-018-0637-x |